<DOC>
	<DOC>NCT01262586</DOC>
	<brief_summary>This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.</brief_summary>
	<brief_title>Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Type 2 diabetes patients on stable metformin 1870 years old Willing to perform at least 4 capillary blood glucose tests per day Type 2 diabetes patients on any other antidiabetic treatment Patients listed in other trials Patients with significant diabetic organ disease or complications. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type II Diabetes Mellitus</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Glimepiride</keyword>
	<keyword>Continuous glucose monitoring</keyword>
</DOC>